Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine for Pediatric Brain Tumors
NCT03068832Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2021
- Primary completion
- Mar 2023
01
Overview
Phase 1, open-label trial of ITK-1 in brain tumor, sponsored by Washington University School of Medicine. Primary endpoint: Adverse Events at 4 months. Planned start Sep 2021; status: withdrawn.
02
Drugs
ITK-1
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT03068832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068832.